In what should come as no surprise to anyone who knows the effects of smoking on patients with asthma, a new report indicates that the latest strings of indoor smoking bans will have a direct impact on reducing emergency room visits due to asthma attacks. Basically, it proves that not subjecting children with breathing problems to tobacco smog is good for their health.
The study was done by researchers at the University of Chicago Medicine, Tech Times reports, and their findings indicate that the ban on smoking indoors results in the drastic reduction of asthma attacks among children that lead to emergency room visits. Three years after the ban was put in effect, ER visits were reduced by 17 percent.
Christina Ciaccio is an expert in pediatric allergy and along with her team, they looked into the emergency room records of over 20 cities where indoor smoking has been banned. After looking at their records from 2000 until 2014, the researchers noted a definite decrease in overall ER visits prompted by breathing problems among asthmatic patients.
This isn’t really surprising since air pollution of any kind has been a major hazard for the 6.3 million American children with asthma living in the U.S. alone. To be fair, other causes of asthma attacks can include everything from car exhaust, factory smoke, allergens, dust, and the occasional overexertion when the weather is cold.
However, as far as causes that induce attacks indoors go, smoking is cited as one of the leading factors, hence the ban. Then again, the researchers themselves acknowledge that their findings are not entirely foolproof since there are some fluctuations in data, MedicalXpress reports. For now, the results of the study simply show that the legislative action pertaining to the smoking ban has a significant impact on public health.


Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



